All In Biotech

Drug Trial Radar · NCT03822975

Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During: a Multicenter, Randomized, Open-label Trial

Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 6,016 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,016

Actual

Start

Feb 14, 2019

Primary completion

May 7, 2022

Study completion May 6, 2023

Sponsor

Lead sponsor
Shenyang Northern HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is aimed to investigate if the bivaliruding with prolonged full dose infusion after PCI is superior to heparin alone in reducing 30-day mortality or major bleeding for patients with STEMI treated with emergency PCI. A total of 6000 STEMI patients will be enrolled and randomly assigned to receive bivalirudin or heparin during emergency PCI in a 1:1 ratio. This study will provide key evidence for peri-operative anticoagulant therapy decisions in STEMI patients.

Conditions

  • ST Elevation Myocardial Infarction

Interventions

  • BivalirudinDrug

    Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.

  • unfractionated HeparinDrug

    Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of all-cause death or BARC type 3~5 bleedingTime frame: 30 days

Locations

85 sites in 1 country. Site status is shown where the registry gives one.

  • Bengbu Second People's Hospital

    Bengbu, Anhui, China

  • Fu Yang People'S Hospital

    Fuyang, Anhui, China

  • Linquan County Peoples Hospital

    Fuyang, Anhui, China

  • NO.2 People's Hospital of Fuyang City

    Fuyang, Anhui, China

  • Taihe County People'S Hospital

    Fuyang, Anhui, China

  • Bozhou Peoples Hospital

    Haozhou, Anhui, China

  • Huainan Oriental Hospital Group Affiliated Hospital of Anhui University of Science & Technology

    Huainan, Anhui, China

  • The First Hospital of Anhui University of Science&Technology

    Huainan, Anhui, China

  • Suzhou Municipal Hospital

    Suzhou, Anhui, China

  • Beijing Luhe Hospital.Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital Yanqing Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Fuling Hospital

    Chongqing, Chongqing Municipality, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Meizhou Peopie's Hospital

    Meizhou, Guangdong, China

  • Yulin First People's Hospital

    Yulin, Guangxi, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Affiliated Hospital Ofzunyi Medical University

    Zunyi, Guizhou, China

  • Hengshuicardiovascularhospital

    Hengshui, Hebei, China

  • Jiaozuo People's Hospital

    Jiaozuo, Henan, China

  • Kaifeng Central Hospital

    Kaifeng, Henan, China

  • Luohe Central Hospital

    Luohe, Henan, China

  • The First People'S Hospital of Ruzhou

    Ruzhou, Henan, China

  • Shangqiu first people's Hospital

    Shangqiu, Henan, China

  • The Third Affiliated Hospital Of Xinxiang Medical University

    Xinxiang, Henan, China

  • Yuzhoucitypeopleshospital

    Yuzhou, Henan, China

  • Fuwai Central China Cardiovascular Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University Center 1

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University Center 2

    Zhengzhou, Henan, China

  • The First People'S Hospital of Xinmi

    Zhengzhou, Henan, China

  • Itchoshtal Tonjinee Colere Hoatono Innehatyor Seene Ano Thohholdcy

    Wuhan, Hubei, China

  • Tongji Hospital Tongji Medical College of Hust

    Wuhan, Hubei, China

  • Wuhanasia Heart Hospital

    Wuhan, Hubei, China

  • Lou Di Central Hospital

    Loudi, Hunan, China

  • Xiangtan Central Hospital

    Xiangtan, Hunan, China

  • Yueyang Central Hospital

    Yueyang, Hunan, China

  • Chifeng College Affiliated Hospital

    Chifeng, Inner Mongolia, China

  • Nanjing Firsthospital

    Nanjing, Jiangsu, China

  • Jiangsutaizhou Peoples Hospital

    Taizhou, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • First Affiliated Hospital Of Gannan Medical University

    Ganzhou, Jiangxi, China

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.